Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Curr Cardiol Rep ; 26(6): 635-641, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38656586

ABSTRACT

PURPOSE OF REVIEW: More than a century since its discovery, the pathogenesis of Chagas heart disease (CHD) remains incompletely understood. The role of derangements in the autonomic control of the heart in triggering malignant arrhythmia before the appearance of contractile ventricular impairment was reviewed. RECENT FINDINGS: Although previous investigations had demonstrated the anatomical and functional consequences of parasympathetic dysautonomia upon the heart rate control, only recently, coronary microvascular disturbances and sympathetic denervation at the ventricular level have been reported in patients and experimental models of CHD, exploring with nuclear medicine methods their impact on the progression of myocardial dysfunction and cardiac arrhythmias. More important than parasympathetic impaired sinus node regulation, recent evidence indicates that myocardial sympathetic denervation associated with coronary microvascular derangements is causally related to myocardial injury and arrhythmia in CHD. Additionally, 123I-MIBG imaging is a promising tool for risk stratification of progression of ventricular dysfunction and sudden death.


Subject(s)
Chagas Cardiomyopathy , Sympathectomy , Humans , Sympathectomy/methods , Chagas Cardiomyopathy/physiopathology , Chagas Cardiomyopathy/surgery , Chagas Cardiomyopathy/complications , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/physiopathology , Heart/innervation , Heart/diagnostic imaging , 3-Iodobenzylguanidine , Sympathetic Nervous System/physiopathology
2.
Pediatr Blood Cancer ; 71(3): e30820, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38153317

ABSTRACT

BACKGROUND: Whole-body metaiodobenzylguanidine (131 I-MIBG) scintigraphy is the gold standard method to detect neuroblastoma; however, it depends on radioactive material and is expensive. In contrast, whole-body magnetic resonance imaging (WB-MRI) is affordable in developing countries and has been shown to be effective in the evaluation of solid tumors. This study aimed to compare the sensitivity and specificity of WB-MRI with MIBG in the detection of primary tumors and neuroblastoma metastases. PROCEDURE: This retrospective study enrolled patients with neuroblastoma between 2013 and 2020. All patients underwent WB-MRI and MIBG at intervals of up to 15 days. The results were marked in a table that discriminated anatomical regions for each patient. Two experts evaluated, independently and in anonymity, the WB-MRI images, and two others evaluated MIBG. The results were compared in terms of sensitivity and specificity, for each patient, considering MIBG as the gold standard. This study was approved by the UNIFESP Ethics Committee. RESULTS: Thirty patients with neuroblastoma were enrolled in this study. The age ranged from 1 to 15 years, with a mean of 5.7 years. The interval between exams (WB-MRI and MIBG) ranged from 1 to 13 days, with an average of 6.67 days. Compared to MIBG, WB-MRI presented a sensitivity and specificity greater than or equal to 90% for the detection of primary neuroblastoma in bones and lymph nodes. When we consider the patient without individualizing the anatomical regions, WB-MRI presented sensitivity of 90% and specificity of 73.33%. CONCLUSION: In conclusion, WB-MRI is a sensitive and specific method to detect neuroblastoma in bone and lymph nodes and highly sensible to primary tumor diagnosis, suggesting that this test is a viable alternative in places where MIBG is difficult to access. Studies with a larger number of cases are necessary for definitive conclusions.


Subject(s)
3-Iodobenzylguanidine , Neuroblastoma , Humans , Infant , Child, Preschool , Child , Adolescent , Whole Body Imaging , Magnetic Resonance Imaging , Retrospective Studies , Radionuclide Imaging , Sensitivity and Specificity , Neuroblastoma/pathology
3.
J Nucl Cardiol ; 29(5): 2274-2291, 2022 Oct.
Article in English | MEDLINE | ID: mdl-34228328

ABSTRACT

BACKGROUND: Advances in diagnosis and treatment of cancer has improved survival but resulted in increased cardiotoxic effects. The decrease in left ventricular ejection fraction (EF), one of the pillars of diagnosis of cardiotoxicity, seems to be a late process in the evolution of the disease, so 123I-metaiodobenzylguanidine (MIBG) cardiac imaging has been proposed to detect early cardiac impairment. The aim of this systematic review was to evaluate the performance of MIBG cardiac scan in this scenario. METHODS AND RESULTS: A systematic search was conducted in five international databases comparing MIBG parameters with EF for evaluation of cardiotoxicity. Twelve studies were included and separated in three groups. First, studies evaluating patients with established cardiotoxicity, in which EF was reduced and MIBG parameters were abnormal. Second, studies analyzing patients during or after treatment compared to controls, with MIBG parameters significantly different between groups in most studies, even when EF remained normal. Finally, studies analyzing anthracycline (ATC) dose-related changes, with alteration in MIBG parameters occurring even when EF was preserved. CONCLUSION: Although studies had high methodological variability, cardiac sympathetic innervation imaging seems to be a promising tool for assessing early cardiotoxicity. Further studies are needed to analyze its diagnostic value in this scenario.


Subject(s)
3-Iodobenzylguanidine , Cardiotoxicity , Anthracyclines/adverse effects , Cardiotoxicity/diagnostic imaging , Heart/innervation , Humans , Stroke Volume , Ventricular Function, Left
5.
Arq. bras. cardiol ; Arq. bras. cardiol;111(2): 182-190, Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-950212

ABSTRACT

Abstract Background: Heart failure (HF) is a severe public health problem because of its high morbidity and mortality and elevated costs, thus requiring better understanding of its course. In its complex and multifactorial pathogenesis, sympathetic hyperactivity plays a relevant role. Considering that sympathetic dysfunction is already present in the initial phases of chronic Chagas cardiomyopathy (CCC) and frequently associated with a worse prognosis, we assumed it could be more severe in CCC than in cardiomyopathies of other etiologies (non-CCC). Objectives: To assess the cardiac sympathetic dysfunction 123I-MIBG) of HF, comparing individuals with CCC to those with non-CCC, using heart transplant (HT) patients as denervated heart parameters. Methods: We assessed 76 patients with functional class II-VI HF, being 25 CCC (17 men), 25 non-CCC (14 men) and 26 HT (20 men), by use of cardiac 123I-metaiodobenzylguanidine 123I-MIBG) scintigraphy, estimating the early and late heart-to-mediastinum ratio (HMR) of 123I-MIBG uptake and cardiac washout (WO%). The 5% significance level was adopted in the statistical analysis. Results: The early and late HMR values were 1.73 ± 0.24 and 1.58 ± 0.27, respectively, in CCC, and 1.62 ± 0.21 and 1.44 ± 0.16 in non-CCC (p = NS), being, however, higher in HT patients (p < 0.001). The WO% values were 41.65 ± 21.4 (CCC), 47.37 ± 14.19% (non-CCC) and 43.29 ± 23.02 (HT), p = 0.057. The late HMR values showed a positive weak correlation with left ventricular ejection fraction (LVEF) in CCC and non-CCC (r = 0.42 and p = 0.045; and r = 0.49 and p = 0.015, respectively). Conclusion: Sympathetic hyperactivity 123I-MIBG) was evidenced in patients with class II-IV HF, LVEF < 45%, independently of the HF etiology, as compared to HT patients.


Resumo Fundamentos: A insuficiência cardíaca (IC) representa um grave problema de saúde pública pela alta morbimortalidade e custos envolvidos, exigindo uma melhor compreensão de sua evolução. Em sua patogênese, complexa e multifatorial, a hiperatividade simpática ocupa relevante papel. Considerando que a disfunção simpática está presente já nas fases iniciais da cardiopatia chagásica crônica (CCC), frequentemente associando-se a um pior prognóstico, supomos que pudesse ser mais grave na CCC que nas demais etiologias (não-CCC). Objetivos: Avaliar a disfunção simpática cardíaca (123I-MIBG) da IC, comparando-se os portadores de CCC aos não-CCC, utilizando os pacientes transplantados cardíacos (TC) como parâmetro de coração desnervado. Métodos: Estudamos 76 pacientes com IC classe funcional II-VI, sendo 25 CCC (17 homens), 25 não-CCC (14 homens) e 26 TC (20 homens), pela cintilografia cardíaca (123I-MIBG), estimando-se a captação (HMR) precoce e tardia e o washout cardíaco (Wc%). Nas análises estatísticas, o nível de significância foi de 5%. Resultados: Os valores da HMR precoce e da tardia foram 1,73 ± 0,24 e 1,58 ± 0,27, respectivamente, na CCC, e 1,62 ± 0,21 e 1,44 ± 0,16 na não-CCC (p = NS), sendo, porém, mais elevados nos TC (p < 0,001). Os valores de Wc% foram 41,65 ± 21,4 (CCC), 47,37 ± 14,19% (não-CCC) e 43,29 ± 23,02 (TC), p = 0,057. Os valores de HMR tardia apresentaram correlação positiva fraca com a fração de ejeção de ventrículo esquerdo (FEVE) na CCC e na não-CCC (r = 0,42 e p = 0,045; e r = 0,49 e p = 0,015, respectivamente). Conclusão: Evidenciou-se a presença de hiperatividade simpática (123I-MIBG) em pacientes com IC classe II-IV, FEVE < 45%, independentemente da etiologia da IC, quando comparados aos pacientes TC.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Chagas Cardiomyopathy/complications , Heart Transplantation , Radiopharmaceuticals/administration & dosage , 3-Iodobenzylguanidine/administration & dosage , Primary Dysautonomias/diagnostic imaging , Heart Failure/diagnostic imaging , Radionuclide Imaging , Chagas Cardiomyopathy/physiopathology , Cross-Sectional Studies , Primary Dysautonomias/etiology , Primary Dysautonomias/physiopathology , Heart Failure/etiology , Heart Failure/physiopathology
7.
J Nucl Cardiol ; 24(1): 256-264, 2017 02.
Article in English | MEDLINE | ID: mdl-26601670

ABSTRACT

PURPOSE: The goal of this study was to evaluate late cardiotoxic effects of anthracyclines (ATC) by evaluating cardiac sympathetic activity in a cohort of asymptomatic patients previously treated with ATC for childhood cancers. METHODS: We studied 89 asymptomatic patients previously treated with ATC with a normal echocardiogram (49 men and 40 women) and a control group of 40 healthy individuals (26 men and 14 women). Both groups underwent planar myocardial 123I-meta-iodobenzylguanidine scintigraphy (123I-mIBG). From these images, the early and late heart-to-mediastinum (H/M) ratio and washout rate (WR) were assessed. RESULTS: The mean survival at the time of the 123I-mIBG scintigraphy was 5.3 ± 3.4 years. Patients treated with ATC had a lower but clinical normal left ventricular ejection fraction (LVEF) compared to controls (60.44 ± 6.5 vs 64.1 ± 6.0%, P < 0.01). Both the late H/M ratio and WR were not able to discriminate ATC treated patients from controls. The cumulative ATC dose was the only independent predictor of the LVEF, explaining approximately 12% of the variation in LVEF (P = 0.01). CONCLUSIONS: Although the pathophysiology behind ATC cardiotoxicity is most likely multifactorial, myocardial sympathetic activity is not associated with a reduction in LVEF 5-years after completion of chemotherapy.


Subject(s)
Anthracyclines/therapeutic use , Autonomic Nervous System Diseases/diagnostic imaging , Autonomic Nervous System Diseases/mortality , Neoplasms/drug therapy , Tomography, Emission-Computed, Single-Photon/methods , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/mortality , 3-Iodobenzylguanidine , Adolescent , Adult , Antineoplastic Agents/adverse effects , Brazil/epidemiology , Cardiotoxicity/diagnostic imaging , Cardiotoxicity/mortality , Causality , Child , Child, Preschool , Comorbidity , Female , Humans , Male , Neoplasms/mortality , Prevalence , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Survival Rate , Treatment Outcome
8.
Arq. bras. cardiol ; Arq. bras. cardiol;106(5): 358-366, May 2016. tab, graf
Article in English | LILACS | ID: lil-784181

ABSTRACT

Abstract Background: More than 50% of the patients with heart failure have normal ejection fraction (HFNEF). Iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy and cardiopulmonary exercise test (CPET) are prognostic markers in HFNEF. Nebivolol is a beta-blocker with vasodilating properties. Objectives: To evaluate the impact of nebivolol therapy on CPET and123I-MIBG scintigraphic parameters in patients with HFNEF. Methods: Twenty-five patients underwent 123I-MIBG scintigraphy to determine the washout rate and early and late heart-to-mediastinum ratios. During the CPET, we analyzed the systolic blood pressure (SBP) response, heart rate (HR) during effort and recovery (HRR), and oxygen uptake (VO2). After the initial evaluation, we divided our cohort into control and intervention groups. We then started nebivolol and repeated the tests after 3 months. Results: After treatment, the intervention group showed improvement in rest SBP (149 mmHg [143.5-171 mmHg] versus 135 mmHg [125-151 mmHg, p = 0.016]), rest HR (78 bpm [65.5-84 bpm] versus 64.5 bpm [57.5-75.5 bpm, p = 0.028]), peak SBP (235 mmHg [216.5-249 mmHg] versus 198 mmHg [191-220.5 mmHg], p = 0.001), peak HR (124.5 bpm [115-142 bpm] versus 115 bpm [103.7-124 bpm], p= 0.043), HRR on the 1st minute (6.5 bpm [4.75-12.75 bpm] versus 14.5 bpm [6.7-22 bpm], p = 0.025) and HRR on the 2nd minute (15.5 bpm [13-21.75 bpm] versus 23.5 bpm [16-31.7 bpm], p = 0.005), but no change in peak VO2 and 123I-MIBG scintigraphic parameters. Conclusion: Despite a better control in SBP, HR during rest and exercise, and improvement in HRR, nebivolol failed to show a positive effect on peak VO2 and 123I-MIBG scintigraphic parameters. The lack of effect on adrenergic activity may be the cause of the lack of effect on functional capacity.


Resumo Fundamento: Mais de 50% dos pacientes com insuficiência cardíaca têm fração de ejeção preservada (ICFEN). A cintilografia marcada com iodo 123 com metaiodobenzilguanidina (123I-MIBG) e o teste cardiopulmonar do exercício (TCPE) são marcadores de prognóstico da ICFEN. O nebivolol é um betabloqueador com propriedade vasodilatadora. Objetivos: Avaliar o impacto da terapia com nebivolol sobre as variáveis da cintilografia com 123I-MIBG e do TCPE em pacientes com ICFEN. Métodos: Vinte e cinco pacientes realizaram cintilografia com 123I-MIBG para avaliar a taxa de washout e a relação coração/mediastino precoce e tardia. Durante o TCPE, foi analisado o comportamento da pressão arterial sistólica (PAS), frequência cardíaca (FC) durante o esforço e a recuperação (FCR) e o consumo de oxigênio (VO2). Após avaliação inicial, separamos nossa amostra em grupos controle versus intervenção, iniciamos o nebivolol e repetimos os exames após 3 meses. Resultados: Após o tratamento, o grupo intervenção apresentou melhora na PAS (149 mmHg [143,5-171 mmHg] versus 135 mmHg [125-151 mmHg, p = 0,016]), FC em repouso (78 bpm [65,5-84 bpm] versus 64,5 bpm [57,5-75,5 bpm, p = 0,028]), PAS no pico do esforço (235 mmHg [216,5-249 mmHg] versus 198 mmHg [191-220,5 mmHg], p = 0,001), FC no pico do esforço (124,5 bpm [115-142 bpm] versus 115 bpm [103,7-124 bpm], p = 0,043) e FCR no 1º minuto (6,5 bpm [4,75-12,75 bpm] versus 14,5 bpm [6,7-22 bpm], p = 0,025) e no 2º minuto (15,5 bpm [13-21,75 bpm] versus 23,5 bpm [16-31,7 bpm], p = 0,005), porém não apresentou mudança no VO2 de pico e nos parâmetros da cintilografia com 123I-MIBG. Conclusão: Apesar de um melhor controle da PAS e na FC em repouso e durante o esforço e uma melhora na FCR, o nebivolol não ocasionou efeito positivo sobre o VO2 de pico e nos parâmetros da cintilografia com 123I-MIBG. A ausência de efeito sobre a atividade adrenérgica pode ser a causa da falta de efeito sobre a capacidade funcional.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Vasodilator Agents/therapeutic use , Radiopharmaceuticals , 3-Iodobenzylguanidine , Nebivolol/therapeutic use , Heart Failure/physiopathology , Oxygen Consumption/drug effects , Stroke Volume/physiology , Blood Pressure/physiology , Radionuclide Imaging , Prospective Studies , Exercise Test/methods , Adrenergic beta-1 Receptor Agonists/therapeutic use , Heart Failure/drug therapy , Heart Failure/diagnostic imaging , Iodine Radioisotopes
11.
J Neuroimaging ; 24(2): 202-4, 2014.
Article in English | MEDLINE | ID: mdl-23279239

ABSTRACT

BACKGROUND: Although metastatic skull lesions of neuroblastoma are not uncommon, brain involvement is infrequent and prompt diagnosis is of utmost importance in such cases. Previous studies have shown that Meta-Iodo-Benzyl-Guanidine (MIBG) scans were not always reliable in detecting central nervous system metastases, however most published reports referred to the Iodine-131 ((131)I)-MIBG scans. Herein, we report an intraventricular metastasis of neuroblastoma diagnosed using an Iodine-123 ((123)I)-MIBG scan, which is increasingly being used in clinical practice and reported as a more accurate method for detecting metastatic lesions. CASE DESCRIPTION: An unusual case of metastatic neuroblastoma to the left lateral ventricle of the brain is presented. Planar (123)I-MIBG scintigraphy showed faint tracer activity close to the midline without asymmetric extensions or abnormal activity in the skull bones. A subsequent brain MR scan revealed an enhancing mass within the left frontal horn consistent with a metastatic lesion. The patient underwent tumor resection with pathology showing neuroblastoma. CONCLUSIONS: Our case shows that (123) I-MIBG scintigraphy can be useful in detecting intraventricular brain metastases of neuroblastoma. Although the (123)I-MIBG scintigraphy has been reported to have a significantly superior sensitivity in monitoring asymptomatic patients with neuroblastoma compared with (131)I-MIBG scans, bone marrow histology, bone scan, CT, and urinary catecholamine levels, further studies may be necessary to evaluate its sensitivity in detecting brain lesions.


Subject(s)
3-Iodobenzylguanidine , Cerebral Ventricle Neoplasms/diagnostic imaging , Cerebral Ventricle Neoplasms/secondary , Neuroblastoma/diagnostic imaging , Neuroblastoma/secondary , Positron-Emission Tomography/methods , Child , Humans , Male , Radiopharmaceuticals
12.
Nucleus (La Habana) ; (52): 54-61, jul.-dic. 2012.
Article in Spanish | LILACS | ID: lil-738971

ABSTRACT

Los tumores neuroendocrinos constituyen un amplio grupo de neoplasias que tienen su origen en diversos tejidos estrechamente ligados por su origen embriológico común a la cresta neural. Estos tumores tienen la capacidad de sintetizar péptidos neurotransmisores y hormonas, además de almacenar catecolaminas. Algunos expresan receptores de somatostatina en sus membranas, lo cual ha permitido que la medicina nuclear pueda participar en el diagnóstico, tratamiento y seguimiento de estas. Dichos tumores por tener su origen en diferentes y variados tipos de tejidos presentan una gran diversidad de signos y síntomas que son diferentes para cada uno de ellos. Estos signos y síntomas dependen fundamentalmente de sus características bioquímicas, dadas por las sustancias que segregan; por su localización, por tanto, del sitio de aparición del tumor, la infiltración local y las posibles metástasis a distancia provocadas por él. El diagnóstico de los tumores neuroendocrinos se realiza por medio de imágenes de medicina nuclear, las cuales se obtienen por diferentes técnicas y radiofármacos como el ácido-dimercapto-succínico (99mTc-DMSA(V)), la metoxi-iso-butil-isonitrilo (99mTc-MIBI), la meta-iodo-bencil-guanidina marcada con 131l o 123l (131l -MIBG o 123l-MIBG), el octreotido marcado con 111l n, la tomografía de emisión de positrones, empleando análogos de somatostatina marcados con 68Ga, así como anticuerpos monoclonales anti antígeno carcinoembrionario. Para el tratamiento de estos tumores en medicina nuclear se emplean fundamentalmente los análogos de somatostatina marcados con 177Lu o con 90Y. El presente trabajo tiene como objetivo mostrar nuestra experiencia en la utilidad de la 131l -MIBG en el diagnóstico y tratamiento de los tumores neuroendocrinos.


Neuroendocrine tumours are neoplasms that arise from various tissues closely linked to the neural crest by their common embryological origin. These tumours have the ability to synthesize neurotransmitter peptides and hormones, as well as to store catecholamines. Some of these tumours express somatostatin receptors at their membranes, what have allowed nuclear medicine to be involved in their diagnosis, treatment and monitoring. Since they arise from different and varied types of tissues, these tumours have a wide range of signs and symptoms different for every one of them. These signs and symptoms mainly depend on their biochemical characteristics, given by the substances they secrete, as well as by their location, and consequently, they also depend on the place where the tumour appears, its local infiltration, and potential long-distance metastasis resulting from the tumour). Neuroendocrine tumours are diagnosed by means of nuclear medicine images, which are obtained by using different techniques and radiopharmaceuticals such as 99mTc dimercaptosuccinic acid (DMSA(V)), 99Tc-methoxy-isobutyl-isonitrile (MIBI), metaiodobenzylguanidine (MIBG) labelled with 131l or 123l (131l -MIBG or 123l-MIBG), 111 pipe n-labelled octreotide, positron emission tomography, using 68Ga-labelled somatostatin analogues and carcinoembryonic antigen monoclonal antibodies. Nuclear medicine uses mainly somatostatin analogues labelled with 90Y or 177 Lu for the treatment of these tumours. This paper is aimed at showing our experience in the use of 131-MIBG for the diagnosis and treatment of neuroendocrine tumours.

13.
Arq. bras. cardiol ; Arq. bras. cardiol;96(5): 370-376, maio 2011.
Article in Portuguese | LILACS | ID: lil-587653

ABSTRACT

FUNDAMENTO: Na insuficiência cardíaca, o teste ergométrico (TE) avalia capacidade funcional, um determinante de prognóstico. A cintilografia com I¹²³ MIBG mostra a ativação simpática cardíaca. OBJETIVO: Avaliar a associação entre as variáveis do TE e as alterações da cintilografia com I¹²³ MIBG. MÉTODOS: Foram submetidos 23 pacientes (FEVE < 45 por cento) à cintilografia com I¹²³ MIBG e separados em: G1) taxa de Washout < 27 por cento; G2) > 27 por cento. Esses pacientes realizaram TE, onde foram analisadas: pressão arterial sistólica no pico do esforço (PASP), frequência cardíaca no pico do esforço (FCP), variação da pressão arterial sistólica intraesforço (Δ PAS), reserva cronotrópica e capacidade funcional em METs. Utilizaram-se para a análise estatística, o teste t de Student ou o teste U de Mann-Whitney, o coeficiente de Spearman e o coeficiente de regressão linear. RESULTADOS: A PASP (G1: 181,00 ± 28,01; G2: 153,27 ± 27,71, p = 0,027), a Δ PAS [G1: 64 (47,5-80,5); G2: 36 (25-47) mmHg, p = 0,015], a FCP (G1: 136,91 ± 19,66; G2: 118,45 ± 13,98 bpm, p = 0,018), a reserva cronotrópica (G1: 70,42 ± 17,94; G2: 49,47 ± 14,89 por cento, p = 0,006) e a capacidade funcional [G1: 8,37 (6,47-10,27); G2: 4,42 (2,46-6,38) METs, p = 0,003] foram menores no G2. Houve correlação negativa entre taxa de Washout com PASP (r = -0,505, p = 0,014), Δ PAS (r = -0,493, p = 0,017) e capacidade funcional (r = -0,646, p = 0,001). Após regressão linear, PASP (r = -0,422, p = 0,016) e capacidade funcional (r = -0,804, p = 0,004) foram associadas com taxa de Washout. CONCLUSÃO: Em pacientes com insuficiência cardíaca, PASP e capacidade funcional foram as varáveis mais associadas com a taxa de Washout.


BACKGROUND: The exercise treadmill test can be used in ventricular dysfunction patients for functional capacity or predicting prognosis. The cardiac image with 123I MIBG shows cardiac sympathetic activation. OBJECTIVE: To evaluate the relationship between exercise treadmill test variables and cardiac image changes in 123I MIBG. METHODS: 23 patients with LVEF < 45 percent performed scintigraphy cardiac with 123I MIBG and divided into two groups. G1: Washout rate < 27 percent; G2: > 27 percent. Systolic blood pressure (SBP), heart rate (HR) and functional capacity were evaluated. It was performed Student t test or Mann-Whitney U test, Spearman coefficient and linear regression. RESULTS: SBP at exercise peak (G1: 181.00 ± 28.01; G2: 153.27 ± 27.71 mmHg, p = 0.027), SBP variation [G1: 64(47.5-80.5); G2: 36(25-47) mmHg, p = 0.015], the HR at exercise peak (G1: 136.91 ± 19.66; G2: 118.45 ± 13.98 bpm, p = 0.018) and chronotropic response (G1: 70.42 ± 17.94; G2: 49.47 ± 14.89 percent, p = 0.006), and functional capacity [G1: 8.37(6.47-10.27); G2: 4.42(2.46-6.38) METs, p = 0.003] were smaller in G2 group. There was negative correlation between Washout rate and SBP at exercise peak (r = -0.505, p = 0.014), variation in SBP (r = -0.493, p = 0.017) and functional capacity (r = -0.646, p = 0.001). Nevertheless, SBP at exercise peak (r = -0.422, p = 0.016) and functional capacity (r = -0.804, p = 0.004) were the only variables associated with Washout rate, after linear regression. CONCLUSION: In heart failure patients, the SBP at exercise peak and functional capacity were the variables associated with Washout rate.


FUNDAMENTOS: En la Insuficiencia Cardíaca, la Ergometría (Test Ergométrico - TE) evalúa la capacidad funcional, un determinante de pronóstico. El centellograma con I¹²³ MIBG muestra la activación simpática cardíaca. OBJETIVO: Evaluar la asociación entre las variables del TE y las alteraciones del centellograma con I¹²³ MIBG. MÉTODOS: Se sometieron 23 pacientes (FEVI < 45 por ciento) a centellograma con I¹²³ MIBG y se separaron en: G1) tasa de Washout < 27 por ciento; G2) > 27 por ciento. Estos pacientes realizaron TE, en el que se analizaron: presión arterial sistólica en el pico del esfuerzo (PAS P), frecuencia cardíaca en el pico del esfuerzo (FCP), variación de la presión arterial sistólica intraesfuerzo (Δ PAS), reserva cronotrópica y capacidad funcional en MET. Para el análisis estadístico se utilizaron el test t de Student o el test U de Mann-Whitney, el coeficiente de Spearman y el coeficiente de regresión lineal. RESULTADOS: La PAS P (G1: 181,00 ± 28,01; G2: 153,27 ± 27,71, p = 0,027), la Δ PAS [G1: 64 (47,5-80,5); G2: 36 (25-47) mmHg, p = 0,015], la FCP (G1: 136,91 ± 19,66; G2: 118,45 ± 13,98 lpm, p = 0,018), la reserva cronotrópica (G1: 70,42 ± 17,94; G2: 49,47 ± 14,89 por ciento, p = 0,006) y la capacidad funcional [G1: 8,37 (6,47-10,27); G2: 4,42 (2,46-6,38) MET, p=0,003] fueron menores menores en el G2. Hubo una correlación negativa entre la tasa de Washout con PASP (r = -0,505, p = 0,014), Δ PAS (r = -0,493, p = 0,017) y capacidad funcional (r = -0,646, p = 0,001). Después de la regresión lineal, PASP (r = -0,422, p = 0,016) y capacidad funcional (r = -0,804, p = 0,004) se asociaron con la tasa de Washout. CONCLUSIÓN: En pacientes con insuficiencia cardíaca, la PASP y la capacidad funcional fueron las variables más asociadas con la tasa de Washout. (Arq Bras Cardiol 2011;96(5):370-376).


Subject(s)
Female , Humans , Male , Middle Aged , Exercise Test/methods , Heart Failure , Heart , Radiopharmaceuticals , Blood Pressure/physiology , Exercise Tolerance/physiology , Heart Failure/physiopathology , Heart Rate/physiology , Linear Models , Statistics, Nonparametric
14.
Rev. chil. radiol ; 8(2): 53-58, 2002. ilus
Article in Spanish | LILACS | ID: lil-627475

ABSTRACT

Nuclear Endocrinology was the first clinical use of radionuclides, five decades ago. From those days to the present, nuclear medicine has a definitive role in the diagnosis of a great variety of clinical situations, from the very frequent thyroid nodule to the unusual neuroendocrine tumors, including parathyroid hyperfunctioning tissue. Radioiodine I131 still remains a very effective treatment for differentiated thyroid cancer and whole body scan with I131 in conjunction with seric Tyroglobulin level are the main follow-up strategies for these tumors. New techniques, like positron emission tomography (PET) and newer radiolabeled peptides, among others, will offer a molecular approach to the 21st century clinical nuclear medicine.


Se presentan las principales indicaciones actuales de los estudios radioisotópicos en endocrinología clínica, y su situación relativa con el resto de las técnicas de imagen no invasivas disponibles en nuestro medio. Se discuten brevemente las nuevas aplicaciones terapéuticas y su potencial desarrollo.


Subject(s)
Humans , Radionuclide Imaging/methods , Endocrine System Diseases/diagnostic imaging , Nuclear Medicine/instrumentation , Nuclear Medicine/methods , Parathyroid Glands/diagnostic imaging , Thyroid Gland/diagnostic imaging , Adrenal Glands/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL